Lisanti Capital Growth LLC Takes $5.48 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Lisanti Capital Growth LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,410 shares of the company's stock, valued at approximately $5,483,000. Krystal Biotech accounts for 1.6% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 14th biggest holding. Lisanti Capital Growth LLC owned 0.11% of Krystal Biotech at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. raised its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after purchasing an additional 141,400 shares in the last quarter. GAMMA Investing LLC lifted its stake in Krystal Biotech by 50,249.4% during the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock worth $21,878,000 after purchasing an additional 121,101 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at $15,989,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on KRYS shares. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Citigroup dropped their price objective on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $211.13.

Krystal Biotech Trading Down 1.4%

KRYS stock traded down $1.99 during trading on Monday, hitting $136.89. The company had a trading volume of 23,105 shares, compared to its average volume of 285,995. The stock has a market cap of $3.96 billion, a PE ratio of 32.92 and a beta of 0.66. The business has a 50-day moving average of $140.66 and a 200-day moving average of $157.54. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).